淋巴瘤资料3.pdf

1542 Rituximab Combined With Cladribine or With Cladribine and Cyclophosphamide in Heavily Pretreated Patients With Indolent Lymphoproliferative Disorders and Mantle Cell Lymphoma Tadeusz Robak, MD, PhD BACKGROUND. In vitro studies have shown synergistic or additive interactions Piotr Smolewski, MD, PhD between rituximab and purine nucleoside analogues. The results of recent clini- Barbara Cebula, PhD cal trials seem to confirm these preclinical observations. Anna Szmigielska-Kaplon, MD METHODS. For the current study, the authors evaluated the feasibility, efficacy, Krzysztof Chojnowski, MD, PhD and toxicity of combined regimens that consisted of either rituximab plus cladri- Jerzy Z. Blonski, MD bine (2-CdA) (the RC regimen) or RC plus cyclophosphamide (the RCC regimen) in the treatment of patients with heavily pretreated, indolent lymphoid malignancies. Department of Hematology, Medical University of Fifty-four adult patients with recurrent or refractory, low-grade non-Hodgkin lym- Lodz, Copernicus Memorial Hospital, Lodz, Poland. phoma (LG-NHL) and B-cell chronic lymphocytic leukemia (B-CLL) were treated according to the RC/RCC regimens. The RC protocol consisted of intravenous rituxi- mab at a dose of 375 mg/m2 on Day 1 and 2-CdA at a dose of .12 mg/kg per day on Days 2 through 6. The RCC protocol consisted of rituximab at a dose of 375 mg/m2 on Day 1, 2-CdA at a dose of 0.12 mg/m2